Last reviewed · How we verify
Insulin Aspart (IAsp)
Insulin aspart is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues.
Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Aspart (IAsp) |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin aspart is a genetically engineered insulin analog with a single amino acid substitution (proline to aspartic acid at position 28 of the B chain) that reduces self-association and enables faster absorption from subcutaneous injection sites compared to human insulin. It binds to insulin receptors on muscle, fat, and liver cells to facilitate glucose transport into cells and promote anabolic metabolism, effectively lowering blood glucose levels.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (NA)
- Fast-Acting Insulin Aspart and Insulin Pump Settings (PHASE4)
- A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification (PHASE3)
- A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients (PHASE4)
- A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (PHASE3)
- Closed-loop Insulin Delivery in the General Ward (NA)
- A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin (PHASE3)
- A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Aspart (IAsp) CI brief — competitive landscape report
- Insulin Aspart (IAsp) updates RSS · CI watch RSS
- University of Aarhus portfolio CI